Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line FOLFOXIRI + bevacizumab vs FOLFOX + bevacizumab in unresectable metastatic colorectal cancer
2014-004436-19Phase 3Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Nov 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, fluorouracil, irinotecan, oxaliplatin and folinic acid in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Progression-free survival 2 (PFS2). Started Nov 2014; status: active.
02
Drugs
bevacizumabfluorouracilirinotecanoxaliplatinfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2014-004436-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004436-19.